Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eAoVCduTtWCjiOszCidyqVCicNMrTD
| Today's Top Story |  |  | | | Health Care & Policy | | | | - FDA will consider expanded use of Genentech's Perjeta regimen
The FDA has accepted Genentech's supplemental biologics license application for use of a Perjeta regimen prior to surgery in patients with HER2-positive early stage breast cancer. The application was granted a priority-review designation. A decision is expected by Oct. 31. RTT News (7/2)       - Pfizer-Bristol's anticoagulant Eliquis achieves main goal in trial
Pfizer and Bristol-Myers Squibb's anticoagulant Eliquis, or apixaban, met the primary goal of a late-stage trial by performing comparably with standard treatment warfarin in reducing recurrence and related deaths in patients with acute venous thromboembolism. Eliquis also reduced the risk of major bleeding by around 70% and clinically relevant nonmajor bleeding by more than 50%. Reuters (6/30), Forbes (6/30) - Mylan gains rights for Zyomyx's HIV/AIDS diagnostic test
Zyomyx has granted Mylan exclusive rights to market its Point-of-Care CD4 Diagnostic Test, a rapid diagnostic assay used in HIV/AIDS therapy that may soon be available on the market. Zyomyx will receive a $12 million investment from Mylan as part of the deal. RTT News (6/30) | Company & Financial News | | | | | Global Developments | | | | | Food & Agriculture | | | | - Rally opposing anti-biotech bill held in Hilo, Hawaii
Pro-biotech groups held a rally in Hilo, Hawaii on Friday to show their opposition to a bill that would ban biotech crops on the island. The Hawaii Papaya Industry Association, Hawaii Dairy, Hawaii Cattlemen's Council, Hawaii Floriculture and Nursery Association, and the Big Island Banana Growers Association participated in the demonstration. Big Island Video News (Hawaii) (6/29) | Industrial & Environmental | | | | - Royal DSM to begin commercial output before licensing cellulosic ethanol tech
Dutch chemicals firm Royal DSM is planning to enter into licensing deals for its cellulosic ethanol process after achieving predictable commercial-scale output at an Iowa facility it is co-developing. The biorefinery, designed to yield 20 million to 25 million gallons of cellulosic ethanol from corn waste, is due to become operational by early 2014, said CEO Feike Sijbesma. Bloomberg (6/28) | News from BIO | | | | - Join us Nov. 11-13 at the BIO Convention in China in Beijing!
The BIO Convention in China brings together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Learn more and register today.
| SmartQuote | | | |  | If at first you don't succeed, try to hide your astonishment."
--Harry Banks,
Scottish soldier  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, July 01, 2013
- Friday, June 28, 2013
- Thursday, June 27, 2013
- Wednesday, June 26, 2013
- Tuesday, June 25, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment